The Growing Strategic Importance of CDMOs in Cell & Gene Therapy
Abstract: Cell and gene therapies continue to expand across oncology, cardiovascular, and CNS diseases, yet production remains limited by talent shortages, complex supply chains, and slow development cycles. This eBook examines the growing strategic role of CDMOs in addressing these constraints and enabling reliable, scalable advancement of CGT programs. It highlights how partners like Catalent support developers through platform-based manufacturing, integrated supply management, and deep analytical and regulatory expertise. Through sections covering iPSC manufacturing innovations, UpTempo plasmid platform advances, emerging needs in CGT 4.0, improved differentiation workflows, and the evolving landscape of AAV potency evaluation, the eBook offers a comprehensive view of the technologies and capabilities that now define high-performing CGT development. Readers gain a clear picture of how CDMO-driven strategies shorten timelines, strengthen CMC decisions, and position programs for clinic and commercial readiness.